Finesse Solutions, Inc., a manufacturer of measurement and control solutions for life sciences process applications, is pleased to announce the dates and topics for CellWorld 2017, a Finesse-sponsored event designed for innovators, visionaries and senior executives in bioprocessing. This invitation-only conference will be held April 25-26, 2017 at the Hilton San Francisco Financial District. It will be a forum for life sciences leaders to discuss the future of biosimilar manufacturing and learn about both disruptive technologies and best practices for continuous processing and personalized medicine.
“We are very excited to host our second international forum in Silicon Valley and discuss the challenges and advances in areas such as CAR-T, applications of CRISPR/CAS9 and gene editing to personalized medicine, continuous processing, and mass production of biosimilars in BRIC countries,” said Dr. Barbara Paldus, CEO of Finesse Solutions. “Our goal is to provide a unique venue for senior leadership in our industry to explore innovation and technology in cutting edge bioprocessing applications.”
Invited speakers will cover advances in both upstream and downstream single-use bioprocessing with a focus on modular automation and data harmonization and analytics as well as small-volume bioproduction for immunotherapy. CellWorld sessions will include the introduction of new tools for end-to-end continuous processing from labscale through manufacturing, including the Finesse G4 automation platform, and the SmartFactory™ that minimizes the required size of new manufacturing plants while efficiently using available capacity.
“To quote the iconic Steve Jobs: ‘The people who are crazy enough to think they can change the world are the ones who do.’” said Dr. Paldus. “It is our hope with CellWorld to bring the community together and foster discussions that will not only accelerate change but introduce new concepts to our industry.”